Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

23 nov. 2015 07h00 HE | Source: Lumos Pharma, Inc.

NewLink Genetics Corporation Announces Clinical Data on Indoximod/Temozolomide Combination in Glioblastoma at Society for Neuro-Oncology Meeting

AMES, Iowa, Nov. 23, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing and commercializing novel...
13 nov. 2015 16h30 HE | Source: Lumos Pharma, Inc.

NewLink Genetics Corporation Announces Phase 2 Data on Indoximod at the San Antonio Breast Cancer Symposium

AMES, Iowa, Nov. 13, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing and commercializing novel...
13 nov. 2015 07h00 HE | Source: Lumos Pharma, Inc.

Paolo Pucci and Nicholas Vahanian Appointed to Board of Directors of NewLink Genetics

AMES, Iowa, Nov. 13, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing and commercializing novel...
10 nov. 2015 07h00 HE | Source: Lumos Pharma, Inc.

NewLink Genetics Corporation Supports 2015 World Pancreatic Cancer Day

AMES, Iowa, Nov. 10, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of developing and commercializing novel immuno-oncology...
09 nov. 2015 07h00 HE | Source: Lumos Pharma, Inc.

NewLink Genetics Corporation Announces Promising Clinical Data on Indoximod at the Society for Neuro-Oncology Annual Meeting

AMES, Iowa, Nov. 09, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing and commercializing novel...
03 nov. 2015 07h00 HE | Source: Lumos Pharma, Inc.

NewLink Genetics Corporation Provides Operational Update and Reports Third Quarter 2015 Financial Results

AMES, Iowa, Nov. 03, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of developing and commercializing novel immuno-oncology...
30 oct. 2015 07h00 HE | Source: Lumos Pharma, Inc.

NewLink Genetics to Participate in Three Upcoming Investor Conferences

AMES, Iowa, Oct. 30, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of developing and commercializing novel immuno-oncology...
23 oct. 2015 07h00 HE | Source: Lumos Pharma, Inc.

NewLink Genetics to Host Its Third Quarter 2015 Earnings Conference Call on November 3, 2015

AMES, Iowa, Oct. 23, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of developing novel immuno-oncology and infectious-disease...
13 oct. 2015 07h00 HE | Source: Lumos Pharma, Inc.

New Study Published in Cell Reports Highlights Indoximod, Demonstrates the Key Role of IDO in Both Local and Systemic Immunosuppression

AMES, Iowa, Oct. 13, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of developing and commercializing novel immuno-oncology...
01 oct. 2015 07h00 HE | Source: Lumos Pharma, Inc.

NewLink Genetics Awarded $18 Million Contract Option from BARDA

AMES, Iowa, Oct. 01, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) announced today that the Biomedical Advanced Research and Development Authority (BARDA) of the United...

Page précédente

Page suivante